Literature DB >> 25283376

Low SVR rates in clinical practice for treating genotype 1 chronic hepatitis C with protease inhibitors boceprevir and telaprevir.

Perry H Dubin1, Seth N Sclair, Rene Rico, Amelia K Boehme, Emerson Y Chen, Paul Martin, William M Lee.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25283376      PMCID： PMC4604568          DOI： 10.1007/s10620-014-3374-1

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  6 in total

1.  Hepatitis C virus treatment: the unyielding chasm between efficacy and effectiveness.

Authors:  Fasiha Kanwal; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2014-03-04       Impact factor: 11.382

2.  Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis.

Authors:  V Saxena; M M Manos; H S Yee; L Catalli; E Wayne; R C Murphy; V A Shvachko; M P Pauly; J Chua; A Monto; N A Terrault
Journal:  Aliment Pharmacol Ther       Date:  2014-03-24       Impact factor: 8.171

3.  Similar effectiveness of boceprevir and telaprevir treatment regimens for hepatitis C virus infection on the basis of a nationwide study of veterans.

Authors:  George N Ioannou; Lauren A Beste; Pamela K Green
Journal:  Clin Gastroenterol Hepatol       Date:  2013-12-17       Impact factor: 11.382

4.  A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.

Authors:  Emerson Y Chen; Seth N Sclair; Frank Czul; Betty Apica; Perry Dubin; Paul Martin; William M Lee
Journal:  Clin Gastroenterol Hepatol       Date:  2013-04-16       Impact factor: 11.382

5.  Effectiveness of telaprevir and boceprevir triple therapy for patients with hepatitis C virus infection in a large integrated care setting.

Authors:  Jennifer C Price; Rosemary C Murphy; Valentina A Shvachko; Mary Pat Pauly; M Michele Manos
Journal:  Dig Dis Sci       Date:  2014-08-08       Impact factor: 3.199

6.  Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.

Authors:  Christophe Hézode; Helene Fontaine; Celine Dorival; Fabien Zoulim; Dominique Larrey; Valerie Canva; Victor De Ledinghen; Thierry Poynard; Didier Samuel; Marc Bourliere; Laurent Alric; Jean-Jacques Raabe; Jean-Pierre Zarski; Patrick Marcellin; Ghassan Riachi; Pierre-Henri Bernard; Veronique Loustaud-Ratti; Olivier Chazouilleres; Armand Abergel; Dominique Guyader; Sophie Metivier; Albert Tran; Vincent Di Martino; Xavier Causse; Thong Dao; Damien Lucidarme; Isabelle Portal; Patrice Cacoub; Jerome Gournay; Veronique Grando-Lemaire; Patrick Hillon; Pierre Attali; Thierry Fontanges; Isabelle Rosa; Ventzislava Petrov-Sanchez; Yoann Barthe; Jean-Michel Pawlotsky; Stanislas Pol; Fabrice Carrat; Jean-Pierre Bronowicki
Journal:  Gastroenterology       Date:  2014-04-03       Impact factor: 22.682
  6 in total
  1 in total

1.  The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort.

Authors:  Midori Kjellin; Terése Wesslén; Erik Löfblad; Johan Lennerstrand; Anders Lannergård
Journal:  Ups J Med Sci       Date:  2018-03-14       Impact factor: 2.384
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.